# Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma

> **NCT01721772** · PHASE3 · COMPLETED · sponsor: **Bristol-Myers Squibb** · enrollment: 418 (actual)

## Conditions studied

- Melanoma

## Interventions

- **BIOLOGICAL:** BMS-936558 (Nivolumab)
- **BIOLOGICAL:** Placebo matching BMS-936558 (Nivolumab)
- **DRUG:** Dacarbazine
- **DRUG:** Placebo matching Dacarbazine

## Key facts

- **NCT ID:** NCT01721772
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01-18
- **Primary completion:** 2014-06-24
- **Final completion:** 2021-05-14
- **Target enrollment:** 418 (ACTUAL)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01721772

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01721772, "Study of Nivolumab (BMS-936558) Compared With Dacarbazine in Untreated, Unresectable, or Metastatic Melanoma". Retrieved via AI Analytics 2026-09-25 from https://api.ai-analytics.org/clinical/NCT01721772. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*